Inozyme Pharma (INZY) Stock Highlights

2.99 | +6.41%

2024-12-21 06:07:36

Inozyme Pharma Inc is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, or genetically engineered, fusion protein that is designed to correct a defect in the mineralization pathway caused by ENPP1 and ABCC6 deficiencies.

Statistics

Range Today

2.75 3.03

Volume Today 932.2K

Range 1 Year

2.38 7.8

Volume 1 Year 115.13M

Range 3 Year

0.99 8

Volume 3 Year 356M

Range 10 Year

0.99 31.65

Volume 10 Year 382.32M

Highlights

Market Capitalization 258.25M (small)

Floating Shares 36.52M

Current Price 2.99

Price To Earnings -2.69

Price To Book 3.12

Earnings Per Share -1.52

Payout Ratio 0%

Performance

Latest +6.41%

1 Month +7.17%

3 Months -47.73%

6 Months -31.26%

1 Year -27.95%

3 Years -60.66%

5 Years -85.63%

10 Years -85.63%

Benchmarks

Market Capitalization

0 / 368

Gross Profits

0 / 278

Total Revenue

0 / 300

Total Rank

0 / 368

Free Cashflow

0 / 352

Performance 5 years

0 / 368

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.